The companies agree to a worldwide Human Platelet Lysate (HPL) Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements, including redirection of HPL customers from Macopharma to PL BioScience.
PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a Patent License and Assignment Agreement with the French company Macopharma S.A.S. As a result of the Agreement, PL BioScience will hereby accept a worldwide license under the patents filed by Macopharma, with a right to sublicense (through multiple tiers), for the duration of the license period.
Read the full press release in the following languages below:
